RTX Corporation (RTX)

RTX is trading near the middle of its 52-week range after a strong third-quarter report, and the analysts who cover it remain positive. The stock closed at $201.29 on November 11, 2026, 4.34% above its 50-day average and 3.06% above its 200-day average, so the trend is up on both measures. Analysts' ratings are weighted toward Buy, and the earnings record shows seven beats in the last eight reports. The main open question is whether the stock can hold above its moving averages and push toward the 52-week high of $226.88.

RTX has beaten the EPS estimate in seven of its last eight reports. The most recent beat, on October 20, 2026, came in at $2.26 against an estimate of $1.78, and the stock rose 0.64% in the first session after it. The July 23, 2026 report produced a 7.33% rise in the first session after the beat, so the market has reacted well to the company's results. The beats have not always produced a rise, however. Three of the seven beats were followed by a lower share price in the first session, so a beat alone does not guarantee a gain.

The trailing P/E ratio of 32.73 is 3.7% below the sector median of 34.0, which places the stock broadly in line with peers. Return on equity of 12.85% is below the sector median of 17.8%, and the net profit margin of 8.75% is held back by a 15.54% operating margin. Debt-to-equity of 0.55 is a moderate level.

The trailing dividend yield is 1.40%, based on an annual dividend of $2.82 per share. Over the past 18 months insiders sold shares worth $54.9M across 21 sales and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market purchases, but the absence of insider buying is worth noting for investors.

The base case is that the stock keeps its upward trend while earnings continue to beat estimates. Analysts expect EPS of $7.70 for 2026, a 22.5% rise, but only $8.06 for 2027, a gain of 4.6%, so the pace of earnings growth is expected to slow after this year. While the price holds above the 20-day EMA of $195.75 and the 200-day SMA of $195.31, the path toward the median analyst target of $235.00 and the high target of $250.00 stays open. A drop below the 200-day SMA would weaken that case and bring the 50-day SMA at $192.92 and the 52-week low of $166.74 into focus. Insider sales of $54.9M over the last 18 months, with no open-market purchases, are a point to watch, although such sales are often planned in advance.